ZYME | Zymeworks Inc.

Healthcare | Biotechnology | Canada | NASD

Index	-	P/E	3.36	EPS (ttm)	2.58	Insider Own	0.10%	Shs Outstand	66.74M	Perf Week	2.97%
Market Cap	544.82M	Forward P/E	-	EPS next Y	-1.33	Insider Trans	-	Shs Float	53.83M	Perf Month	2.60%
Income	172.60M	PEG	0.31	EPS next Q	-0.47	Inst Own	78.40%	Short Float / Ratio	10.85% / 10.22	Perf Quarter	8.24%
Sales	446.10M	P/S	1.22	EPS this Y	146.40%	Inst Trans	-0.58%	Short Interest	5.84M	Perf Half Y	12.31%
Book/sh	7.10	P/B	1.22	EPS next Y	22.70%	ROA	36.00%	Target Price	14.07	Perf Year	24.21%
Cash/sh	5.42	P/C	1.60	EPS next 5Y	11.00%	ROE	50.50%	52W Range	4.11 - 10.80	Perf YTD	10.31%
Dividend	-	P/FCF	5.07	EPS past 5Y	42.60%	ROI	24.30%	52W High	-19.72%	Beta	0.93
Dividend %	-	Quick Ratio	6.30	Sales past 5Y	51.50%	Gross Margin	-	52W Low	110.95%	ATR	0.48
Employees	304	Current Ratio	6.30	Sales Q/Q	1756.90%	Oper. Margin	39.40%	RSI (14)	46.04	Volatility	4.78% 5.46%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	69.20%	Profit Margin	38.70%	Rel Volume	0.37	Prev Close	8.49
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 08 AMC	Payout	0.00%	Avg Volume	571.42K	Price	8.67
Recom	1.90	SMA20	-4.45%	SMA50	-4.41%	SMA200	10.91%	Volume	210,612	Change	2.12%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-21-23	Resumed	Wells Fargo	Overweight	$12
Jan-04-23	Reiterated	H.C. Wainwright	Neutral	$10 → $8
Dec-20-22	Upgrade	Jefferies	Hold → Buy	$7.70 → $11
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral	$40 → $8
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$8
Oct-04-22	Resumed	Wells Fargo	Overweight	$45 → $9
May-05-22	Upgrade	Guggenheim	Neutral → Buy	$14
Mar-15-22	Initiated	Evercore ISI	Outperform	$15
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold	$32
Mar-31-21	Initiated	Credit Suisse	Outperform	$55
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$41
Feb-08-21	Resumed	H.C. Wainwright	Buy	$57
Jan-25-21	Downgrade	Citigroup	Buy → Neutral	$50 → $53
Sep-29-20	Resumed	JP Morgan	Neutral	$48
Aug-06-20	Initiated	SVB Leerink	Outperform	$45
Jan-10-20	Initiated	Wolfe Research	Outperform	$61
Dec-09-19	Initiated	JP Morgan	Neutral
Nov-25-19	Initiated	H.C. Wainwright	Buy	$65

Show Previous Ratings

Jun-02-23 06:41PM	Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers (PR Newswire)
Jun-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-18-23 08:30AM	Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer (GlobeNewswire)
May-08-23 04:05PM	Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Apr-18-23 04:05PM	Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Apr-17-23 08:30AM	Zymeworks To Host First Quarter 2023 Results Conference Call (Business Wire)
Apr-10-23 08:30AM	Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors (Business Wire)
Apr-03-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire)
Mar-14-23 04:30PM	Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-07-23 04:05PM	Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-28-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire)
Feb-21-23 08:30AM	Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call (Business Wire)
Jan-25-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire)
Jan-19-23 07:45AM	Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma (PR Newswire)
04:15PM	Loading…
Jan-04-23 04:15PM	Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023 (Business Wire)
Dec-21-22 07:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (Business Wire) +23.59%
07:30AM	Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab (PR Newswire)
Dec-19-22 07:00AM	Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab (Business Wire) +5.11%
Dec-14-22 04:15PM	Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (Business Wire)
Dec-09-22 08:00AM	New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS (Business Wire) -5.23%
Dec-05-22 08:30AM	Zymeworks to Transfer Stock Listing to Nasdaq (Business Wire)
Nov-29-22 08:30AM	Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals (Business Wire)
Nov-24-22 12:20PM	Why Zymeworks Inc. (ZYME) Might be Well Poised for a Surge (Zacks)
Nov-22-22 09:55AM	Wall Street Analysts Believe Zymeworks Inc. (ZYME) Could Rally 59%: Here's is How to Trade (Zacks)
08:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (Business Wire)
Nov-21-22 12:22PM	Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option (Zacks)
09:55AM	Zymeworks Inc. (ZYME) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
09:00AM	Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS) (Business Wire)
Nov-08-22 05:45PM	Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:22PM	Loading…
04:22PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results (Business Wire)
Nov-02-22 10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -5.64%
Nov-01-22 10:01AM	Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-31-22 04:42PM	Why Shares of Zymeworks Rose 12.18% on Monday (Motley Fool) +11.73%
Oct-21-22 01:35PM	Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline (Benzinga)
Oct-20-22 01:36PM	Zymeworks (ZYME) Up on Licensing Deal With Jazz Pharmaceuticals (Zacks)
11:48AM	Zymeworks Inc. (ZYME) Surges 15.9%: Is This an Indication of Further Gains? (Zacks)
08:30AM	Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms (Business Wire)
Oct-19-22 11:08AM	Why Zymeworks Stock Is Soaring Today (Motley Fool) +15.86%
08:38AM	Zymeworks, Jazz agree to licensing deal for cancer drug (MarketWatch)
07:29AM	Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal (Benzinga)
06:07AM	Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab (Business Wire)
06:00AM	Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody (PR Newswire)
Oct-18-22 08:30AM	Zymeworks to Host Third Quarter Results Conference Call (Business Wire)
Oct-13-22 07:00AM	Zymeworks Completes Plan to Become Delaware Corporation (Business Wire)
Oct-07-22 04:15PM	Zymeworks Announces Results of Special Meeting (Business Wire)
Oct-04-22 08:30AM	Zymeworks Reminds Shareholders to Vote FOR its Redomicile (Business Wire)
Oct-03-22 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day (Business Wire)
Sep-29-22 07:30AM	Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last? (Zacks)
Sep-26-22 04:15PM	Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile (Business Wire)
Sep-16-22 08:30AM	Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile (Business Wire)
Sep-13-22 09:34AM	Zymeworks Highlights Early Data From Zanidatamab Zovodotin Trial In HER2-Positive Tumors (Benzinga)
Sep-08-22 04:15PM	Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware (Business Wire) +9.03%
Sep-04-22 06:05PM	Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers (Business Wire)
Aug-04-22 08:35PM	Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +5.59%
04:15PM	Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-01-22 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire)
Jul-27-22 08:45AM	Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-25-22 08:30AM	Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris (Business Wire) -6.70%
Jul-22-22 08:30AM	Zymeworks Reports Inducement Grant to New Chief Scientific Officer (Business Wire) -8.06%
Jul-21-22 08:30AM	Zymeworks to Host Second Quarter Results Conference Call (Business Wire)
Jul-15-22 08:00AM	Zymeworks Announces Plan to Become a Delaware Corporation (Business Wire)
Jun-27-22 08:30AM	Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer (Business Wire)
Jun-10-22 09:57AM	Drug developer Zymeworks adopts 'poison pill' to keep All Blue at bay (Reuters)
09:15AM	Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company (Business Wire)
May-27-22 09:57AM	Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting (MarketWatch) +7.85%
05:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (Business Wire)
May-26-22 05:00PM	Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022 (Business Wire) +7.60%
May-20-22 03:13PM	Zymeworks Turns Down All Blue's Hostile Bid (Benzinga)
09:53AM	Zymeworks rejects 'unsolicited, opportunistic' buyout bid by UAE-based All Blue Falcons (MarketWatch)
09:15AM	Zymeworks Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal (Business Wire)
May-19-22 01:00PM	ALL BLUE CAPITAL EXPANDS ITS LEADERSHIP TEAM TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS INC. (PR Newswire) +12.57%
May-04-22 06:25PM	Zymeworks Inc. (ZYME) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:15PM	Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results (Business Wire)
May-03-22 03:27PM	ALL BLUE CAPITAL ANNOUNCES LEADERSHIP TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS, INC. (PR Newswire)
02:59PM	Former AstraZeneca oncology head to help All Blue in Zymeworks takeover bid (Reuters)
May-02-22 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire) +12.44%
06:36AM	Zymeworks Inc. (ZYME) Surges 23.2%: Is This an Indication of Further Gains? (Zacks)
Apr-29-22 10:53AM	Why Zymeworks Stock Is Rocketing Higher on Friday (Motley Fool) +23.19%
Apr-28-22 09:00PM	Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons (Business Wire)
05:15PM	CORRECTED-UPDATE 3-All Blue Capital in $773 mln bid for Zymeworks (Reuters)
04:39PM	All Blue Capital in $773 million bid for Zymeworks (Reuters)
08:30AM	Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer (Business Wire)
Apr-27-22 04:15PM	Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
03:03PM	Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-19-22 04:15PM	Zymeworks to Host First Quarter 2022 Results Conference Call (Business Wire)
Apr-14-22 06:40AM	Companies Like Zymeworks (NYSE:ZYME) Could Be Quite Risky (Simply Wall St.)
Apr-06-22 09:26AM	HC Wainwright Sees 'Multiple Catalyst Opportunities' After Atreca Inks Licensing Pact With Zymeworks (Benzinga) +6.50%
Apr-05-22 04:01PM	Atreca Announces Expansion of Preclinical Pipeline (GlobeNewswire)
Apr-01-22 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire)
Mar-03-22 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire) -6.23%
Feb-28-22 06:37AM	One Zymeworks Inc. (NYSE:ZYME) insider upped their stake by 236% in the previous year (Simply Wall St.)
Feb-24-22 06:20PM	Zymeworks Inc. (ZYME) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results (Business Wire)
Feb-17-22 03:02PM	Earnings Preview: Zymeworks Inc. (ZYME) Q4 Earnings Expected to Decline (Zacks)
Feb-15-22 05:25PM	CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-08-22 04:15PM	Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call (Business Wire)
Feb-03-22 04:15PM	Zymeworks Announces Participation in Upcoming Investor Conferences (Business Wire)
Feb-01-22 04:49AM	Zymeworks Inc. (ZYME) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks) -5.51%
Jan-31-22 12:05PM	Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares (Business Wire) +5.33%

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include Zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EcoR1 Capital, LLC	10% Owner	Mar 28	Buy	8.00	200,000	1,600,000	10,087,473	Mar 30 05:47 PM
Klompas Neil A	President & COO	Mar 10	Option Exercise	0.00	5,208	0	20,009	Mar 14 05:00 PM
Klompas Neil A	President & COO	Mar 10	Sale	7.83	2,977	23,298	17,032	Mar 14 05:00 PM
EcoR1 Capital, LLC	10% Owner	Jan 20	Buy	9.88	163,400	1,615,095	9,887,473	Jan 23 06:00 PM
EcoR1 Capital, LLC	10% Owner	Jan 19	Buy	9.49	144,100	1,367,639	9,724,073	Jan 23 06:00 PM
EcoR1 Capital, LLC	10% Owner	Jan 18	Buy	10.00	203,000	2,029,046	9,579,973	Jan 18 06:27 PM
EcoR1 Capital, LLC	10% Owner	Jan 17	Buy	9.80	440,000	4,313,848	9,376,973	Jan 18 06:27 PM
EcoR1 Capital, LLC	10% Owner	Jan 13	Buy	9.81	342,100	3,354,633	8,936,973	Jan 18 06:27 PM
EcoR1 Capital, LLC	10% Owner	Jan 11	Buy	7.87	106,300	836,911	8,594,873	Jan 12 04:47 PM
EcoR1 Capital, LLC	10% Owner	Jan 10	Buy	7.65	920,000	7,037,172	8,488,573	Jan 12 04:47 PM
Astle Christopher	SVP & Chief Financial Officer	Dec 12	Option Exercise	0.00	1,550	0	2,220	Dec 14 08:00 PM
Astle Christopher	SVP & Chief Financial Officer	Dec 12	Sale	6.01	887	5,331	1,333	Dec 14 08:00 PM
Josephson Neil	Chief Medical Officer	Nov 10	Option Exercise	0.00	5,885	0	16,924	Nov 14 09:41 PM
Josephson Neil	Chief Medical Officer	Nov 10	Sale	8.10	2,475	20,045	14,449	Nov 14 09:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZYME | Zymeworks Inc.

Upgrade your FINVIZ experience